43,005 Shares in DexCom, Inc. $DXCM Bought by SWS Partners

Key Points

• SWS Partners acquired 43,005 DexCom shares during the second quarter, worth approximately $2.9 million. Institutional investors collectively own 97.75% of the company.
• DexCom insiders sold 99,794 shares valued at $7.37 million in the last quarter, though the transactions were conducted under pre-arranged Rule 10b5-1 trading plans.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an $88.71 price target. DexCom also exceeded quarterly expectations, reporting $0.70 EPS and $1.31 billion in revenue, up 13.1% year over year.

SWS Partners bought a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 43,005 shares of the medical device company's stock, valued at approximately $2,896,000.

Several other institutional investors have also recently bought and sold shares of the company. Reflection Asset Management acquired a new stake in shares of DexCom in the fourth quarter valued at about $25,000. Ascentis Independent Advisors acquired a new position in shares of DexCom during the 1st quarter worth about $25,000. MCF Advisors LLC acquired a new position in shares of DexCom during the 4th quarter worth about $32,000. Wellington Grp LLC boosted its stake in DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company's stock valued at $34,000 after purchasing an additional 475 shares during the period. Finally, DV Equities LLC acquired a new stake in DexCom in the 4th quarter valued at approximately $36,000. Institutional investors own 97.75% of the company's stock.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the company's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the sale, the executive vice president directly owned 106,353 shares in the company, valued at $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,911 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total value of $364,052.43. Following the transaction, the executive vice president owned 95,450 shares of the company's stock, valued at $7,075,708.50. This represents a 4.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 99,794 shares of company stock worth $7,373,321 in the last quarter. Corporate insiders own 0.28% of the company's stock.

Analyst Ratings Changes

DXCM has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft started coverage on DexCom in a research report on Tuesday, June 23rd. They issued a "buy" rating and a $86.00 price target on the stock. Bank of America lowered their price objective on shares of DexCom from $100.00 to $80.00 and set a "buy" rating on the stock in a research note on Monday, May 18th. Piper Sandler reaffirmed an "overweight" rating and set a $95.00 target price (up from $88.00) on shares of DexCom in a research report on Friday, July 31st. Canaccord Genuity Group set a $90.00 target price on shares of DexCom and gave the stock a "buy" rating in a research report on Monday, August 3rd. Finally, Barclays reiterated an "underweight" rating and set a $64.00 target price (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $88.71.

DexCom Stock Performance

NASDAQ:DXCM opened at $89.75 on Friday. The firm has a market capitalization of $33.87 billion, a PE ratio of 35.47, a price-to-earnings-growth ratio of 1.54 and a beta of 1.41. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $91.96. The firm has a 50-day moving average price of $76.08 and a 200 day moving average price of $70.36.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. During the same period in the prior year, the company posted $0.48 EPS. The company's revenue was up 13.1% compared to the same quarter last year. Research analysts anticipate that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source